Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific receives US FDA approval for expanded labelling of Farapulse PFA System: Marlborough, Massachusetts Tuesday, July 8, 2025, 11:00 Hrs [IST] Boston Scientific Corp ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) ...

BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.